Glick, B., Lain, E., Lin, T. and Israel, R. 2019. Efficacy of Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Fixed Combination in the Treatment of Moderate Plaque Psoriasis: Indirect Comparison Between Pooled Phase 3 Trials of HP/TAZ and Oral Treatment (Apremilast). SKIN The Journal of Cutaneous Medicine. 3, (Nov. 2019), S30. DOI:https://doi.org/10.25251/skin.3.supp.30.